Engineered for Injectable Drug Delivery Excellence: The Bridgeton Site

As injectable drug delivery continues to evolve — driven by biologics, GLP‑1 therapies, and increasingly complex formulations—manufacturing sites must deliver more than capacity alone. Bridgeton was designed as an integrated injectable drug delivery hub, combining formulation, aseptic fill‑finish, assembly, and final packaging within a single cGMP‑compliant environment to simplify workflows and minimize handoffs.

Four high‑speed filling lines support vials, cartridges, and prefilled syringes, each leveraging isolator technology, controlled inert environments, and real‑time process monitoring to maintain sterility and precision. With the ability to produce more than 150 million units annually, the site offers the flexibility to scale seamlessly from early clinical batches to full commercial supply. Additional cleanroom capacity, digital‑first infrastructure, and embedded quality oversight further enable adaptability as delivery formats and regulatory expectations evolve. Together, these capabilities create a streamlined, resilient platform for advancing complex injectable therapies efficiently and reliably.